TP53 and cancer: Currently, “liquid biopsy”, “mutant KRAS”, “blockade”, “biomarker”, “tp53”, “promotes”, etc. reflect that liquid biopsy has great potential for early cancer diagnosis, KRAS mutation detection and appropriate treatment strategies firstly (37, 38).